Search

The purpose of this study was to conduct a cohort analysis six years after the introduction of medical care for HIV-infected patients in the first voluntary and anonymous screening center in Senegal. This paper provides a retrospective descriptive study of the medical records of HIV-infected patients followed between 2004 and 2009. The center provided care to 389 patients over the course of the six-year period. The median age of patients was 36 years [17- 69 years], with a sex-ratio (F/M) of 2.5. Access to care was mainly by voluntary screening (313 cases). Two thirds (65%) of patients were either asymptomatic or pauci-symptomatic (WHO Stage I/II). Prurigo (20%) and sexually transmitted infections (19%) were the main diseases diagnosed among patients. 66.6% of patients had a CD4+ cell count ? 200/mm3. By the end of 2009, two hundred and thirty-five patients were still being followed. The rate of patients lost to follow-up was 29%, while the lethality rate was 6%. The assessment of the activities of the voluntary, anonymous and free screening center shows the importance of screening centers in the fight to promote knowledge about HIV infection.

The diagnostic potential of RT-PCR for detection of bluetongue virus (BTV) ribonucleic acid (RNA) sequence in cell culture and tissue samples from infected ruminants from United States, Sudan, South Africa and Senegal, was evaluated. The non structural protein 1 (NS1) gene of North American BTV serotype 11 was targeted for PCR amplification. The United States BTV serotypes 2, 10, 11, 13 and 17 and the Sudanese BTV serotypes 1, 2, 4 and 16 and BTV serotype 4 from South Africa and BTV serotype 2 from Senegal were studied. RNAs from all BTV field isolates used in this study, propagated in cell cultures, were detected by the described RT-PCR-based assay. The first specific 790bp BTV PCR products were amplified using a pair of outer primers (BTV1 and BTV2). Specificity of the PCR products was confirmed by a nested amplification of a 520bp PCR product using a pair of internal (nested) primers (BTV3 and BTV4). The BTV PCR products were visualized on ethidium bromide-stained agarose gels. Amplification products were not detected when the RT-PCR-based assay was applied to RNAs from closely related orbiviruses including, epizootic hemorrhagic disease virus (EHDV) prototypes serotypes 1, 2, 4; RNA from Sudanese isolate of palyam orbiviruses serogroup and total nucleic acid extracts from uninfected Vero cells. Application of the nested BTV RT-PCR to clinical samples resulted in amplification of BTV RNA from blood and serum samples from goats experimentally infected with BTV4 and from naturally infected sheep, goats, cattle and deer. The results of this study indicated that this RT-PCR assay could be applied for rapid detection of BTV, in cell culture and clinical samples from susceptible ruminants during an outbreak of the disease, in the United States and African.

A survey was carried out in two goat herds during a single peste des petits ruminant (PPR) outbreak. Clinical examination showed that animals belonging to the West African Dwarf species had severe symptoms while those belonging to the West African long-legged species had mild symptoms. To confirm and to monitor the disease in each species, the study required specific monoclonal antibody-based diagnostic tools. An association of shedding of PPR virus (PPRV) and acute or mild clinical signs of the disease could be demonstrated by the rinderpest virus (RPV)/PPRV immunocapture ELISA assay. Between 85 and 100% of nasal secretions obtained from clinically diseased goats during the PPR outbreak reacted positively. Parallel serological surveillance for specific measurement of PPR antibodies revealed that between 34.4 and 88.5% of animals with no detectable virus were, however, able to seroconvert and therefore seemed to demonstrate that PPR subclinical infections do occur. Antibodies were shown to impair the RP heterologous vaccination. This evaluation offers new prospects for diagnosis and management of PPRV infection as well as for RPV control.

Rinderpest is an acute and highly contagious viral disease of ruminants, often resulting in greater than 90% mortality. We previously reported the development of first- and second-generation recombinant vaccinia virus vaccines which provide complete protection against rinderpest virus (RPV) and peste-des-petits ruminants virus (PPRV). These vaccines are safe even for immunodeficient mice and macaques with acquired immunodeficiency syndrome. We developed a third-generation recombinant vaccinia virus vaccine (v2RVFH) that expresses the fusion and haemagglutinin genes of RPV under strong synthetic vaccinia virus promoters. Cattle vaccinated intramuscularly with as little as 10(3) plaque-forming units (PFU) of v2RVFH were completely protected from rinderpest. Vaccinated animals did not develop pock lesions or transmit v2RVFH to contact animals. Cattle vaccinated with a standard dose of 10(8) PFU of v2RVFH developed long-term, sterilizing immunity against rinderpest. Thus, v2RVFH is safe, efficacious, heat stable, inexpensive, easily administered, and allows serological differentiation between vaccinated and infected animals. To aid in diagnosis and differentiation of vaccinated from infected animals, we developed indirect ELISAs (iELISAs) that use baculovirus-expressed RPV or PPRV nucleoprotein as coating antigens. A single larva contains enough viral antigen to test more than 10,000 serum samples, in duplicate. African scientists trained at the ILMB successfully transferred the iELISA kit technology to more than 30 countries in Africa, providing a model for technology transfer among developing countries. Vaccination with v2RVFH, in conjunction with the iELISA kits, greatly enhances the prospects for global eradication of rinderpest, as developing nations achieve independence in control efforts.

From 1986 to 1988 a sero-epidemiological survey was carried out in Mali by ILCA to identify the small ruminant main respiratory viruses. The results of this investigation shows an endemic condition. Regardless of the virus species involved, neutralizing antibodies were detected in adults as well as in young stocks. New researches are necessary to set forth a consistent and effective policy of prophylaxis or treatment according to the case concerned.